 Amid a soft opening performance for the major equity indices, Edesa Biotech NASDAQ: EDSA shot up 7 against the prior session before dipping into negative territory during the afternoon session. The biopharmaceutical company, which specializes in inflammatory and immune-related diseases, announced positive Phase 2 results for its monoclonal antibody candidate targeting respiratory symptoms. 